Preoperative intravenous iron therapy in patients with gastric cancer

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519738-21-01

Enrollment

202

Registered

2024-12-16

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with gastric cancer

Brief summary

Number of patients receiving transfusions

Detailed description

Postoperative Hb level, complications and quality of life

Interventions

DRUGFerinject 50 mg Fe/ml injektio-/infuusioneste

DRUGdispersio.

DRUGNatriumklorid 9 mg/ml “Fresenius Kabi“

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of patients receiving transfusions	—

Secondary

Measure	Time frame
Postoperative Hb level, complications and quality of life	—

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026